Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
Total raised: $12M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.12.2023 | Seed | $12M | - |
Mentions in press and media 2
| Date | Title | Description |
| 06.12.2023 | Ability Biologics Closes $12M Seed Funding | Ability Biologics, a Montreal, Canada-based premier cell targeting company, closed a $12m financing round. The round was led by founding investor Amplitude Ventures with participation from Fonds de solidarité FTQ, Charles River Laboratories... |
| - | Ability biologics | “Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.” |